{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:48:00Z","timestamp":1783774080728,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T00:00:00Z","timestamp":1545436800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005039","name":"Leiden University Medical Center","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005039","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00428-018-2503-1","type":"journal-article","created":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T05:57:27Z","timestamp":1545458247000},"page":"375-381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["M-CSF and IL-34 expression as indicators for growth in sporadic vestibular schwannoma"],"prefix":"10.1007","volume":"474","author":[{"given":"W. M.","family":"de Vries","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. H.","family":"Briaire-de Bruijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. P. G.","family":"van Benthem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. G. L.","family":"van der Mey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. C. W.","family":"Hogendoorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,22]]},"reference":[{"issue":"1","key":"2503_CR1","first-page":"93","volume":"26","author":"DG Evans","year":"2005","unstructured":"Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R (2005) Incidence of vestibular schwannoma and neurofibromatosis 2 in the north west of England over a 10-year period: higher incidence than previously thought. OtolNeurotol 26(1):93\u201397","journal-title":"OtolNeurotol"},{"issue":"5","key":"2503_CR2","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/0092-8674(93)90406-G","volume":"72","author":"JA Trofatter","year":"1993","unstructured":"Trofatter JA, MacCollin MM, Rutter JL, Murrell JR, Duyao MP, Parry DM, Eldridge R, Kley N, Menon AG, Pulaski K (1993) A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72(5):791\u2013800","journal-title":"Cell"},{"issue":"6","key":"2503_CR3","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1093\/hmg\/3.6.885","volume":"3","author":"J Sainz","year":"1994","unstructured":"Sainz J, Huynh DP, Figueroa K, Ragge NK, Baser ME, Pulst SM (1994) Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. Hum Mol Genet 3(6):885\u2013891","journal-title":"Hum Mol Genet"},{"issue":"6429","key":"2503_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/363515a0","volume":"363","author":"GA Rouleau","year":"1993","unstructured":"Rouleau GA, Merel P, Lutchman M, Sanson M, Zucman J, Marineau C, Hoang-Xuan K, Demczuk S, Desmaze C, Plougastel B (1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363(6429):515\u2013521","journal-title":"Nature"},{"issue":"2","key":"2503_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.otc.2011.12.008","volume":"45","author":"SE Stangerup","year":"2012","unstructured":"Stangerup SE, Caye-Thomasen P (2012) Epidemiology and natural history of vestibular schwannomas. Otolaryngol Clin N Am 45(2):257\u2013268","journal-title":"Otolaryngol Clin N Am"},{"issue":"5","key":"2503_CR6","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1227\/NEU.0b013e3181f22660","volume":"67","author":"SE Stangerup","year":"2010","unstructured":"Stangerup SE, Tos M, Thomsen J, Caye-Thomasen P (2010) True incidence of vestibular schwannoma? Neurosurgery 67(5):1335\u20131340","journal-title":"Neurosurgery"},{"issue":"5","key":"2503_CR7","first-page":"690","volume":"21","author":"MF Howitz","year":"2000","unstructured":"Howitz MF, Johansen C, Tos M, Charabi S, Olsen JH (2000) Incidence of vestibular schwannoma in Denmark, 1977-1995. Am J Otol 21(5):690\u2013694","journal-title":"Am J Otol"},{"issue":"1","key":"2503_CR8","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/neuonc\/nop010","volume":"12","author":"VF Mautner","year":"2010","unstructured":"Mautner VF, Nguyen R, Kutta H, Fuensterer C, Bokemeyer C, Hagel C, Friedrich RE, Panse J (2010) Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol 12(1):14\u201318","journal-title":"Neuro Oncol"},{"issue":"7","key":"2503_CR9","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1097\/MAO.0b013e3181eb328a","volume":"31","author":"SR Plotkin","year":"2010","unstructured":"Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG (2010) Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol 31(7):1135\u20131143","journal-title":"Otol Neurotol"},{"issue":"9","key":"2503_CR10","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1158\/0008-5472.CAN-09-3107","volume":"70","author":"HK Wong","year":"2010","unstructured":"Wong HK, Lahdenranta J, Kamoun WS, Chan AW, McClatchey AI, Plotkin SR, Jain RK, di TE (2010) Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res 70(9):3483\u20133493","journal-title":"Cancer Res"},{"key":"2503_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jocn.2016.05.003","volume":"32","author":"I Paldor","year":"2016","unstructured":"Paldor I, Chen AS, Kaye AH (2016) Growth rate of vestibular schwannoma. J Clin Neurosci 32:1\u20138","journal-title":"J Clin Neurosci"},{"issue":"2","key":"2503_CR12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1097\/MAO.0b013e31827c9fbf","volume":"34","author":"M Vries de","year":"2013","unstructured":"de Vries M, Briaire-de BI, Malessy MJ, de Bruine SF, van der Mey AG, Hogendoorn PC (2013) Tumor-associated macrophages are related to volumetric growth of vestibular schwannomas. Otol Neurotol 34(2):347\u2013352","journal-title":"Otol Neurotol"},{"issue":"6","key":"2503_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s00428-012-1236-9","volume":"460","author":"M Vries de","year":"2012","unstructured":"de Vries M, Hogendoorn PC, Briaire-de BI, Malessy MJ, van der Mey AG (2012) Intratumoral hemorrhage, vessel density, and the inflammatory reaction contribute to volume increase of sporadic vestibular schwannomas. Virchows Arch 460(6):629\u2013636","journal-title":"Virchows Arch"},{"issue":"7203","key":"2503_CR14","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani A, Allavena P, Sica A, Balkwill F (2008) Cancer-related inflammation. Nature 454(7203):436\u2013444","journal-title":"Nature"},{"issue":"5","key":"2503_CR15","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1189\/jlb.0609385","volume":"86","author":"G Solinas","year":"2009","unstructured":"Solinas G, Germano G, Mantovani A, Allavena P (2009) Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 86(5):1065\u20131073","journal-title":"J Leukoc Biol"},{"issue":"2","key":"2503_CR16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/path.2803","volume":"223","author":"M Allen","year":"2011","unstructured":"Allen M, Louise JJ (2011) Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 223(2):162\u2013176","journal-title":"J Pathol"},{"issue":"7","key":"2503_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P (2017) Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 14(7):399\u2013416","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2503_CR18","first-page":"23","volume":"1865","author":"Q Lahmar","year":"2016","unstructured":"Lahmar Q, Keirsse J, Laoui D, Movahedi K, Van Overmeire E, Van Ginderachter JA (2016) Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment. Biochim Biophys Acta 1865(1):23\u201334","journal-title":"Biochim Biophys Acta"},{"issue":"7","key":"2503_CR19","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.4049\/jimmunol.1100130","volume":"187","author":"J Svensson","year":"2011","unstructured":"Svensson J, Jenmalm MC, Matussek A, Geffers R, Berg G, Ernerudh J (2011) Macrophages at the fetal-maternal interface express markers of alternative activation and are induced by M-CSF and IL-10. J Immunol 187(7):3671\u20133682","journal-title":"J Immunol"},{"issue":"5","key":"2503_CR20","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.3892\/ijo.2016.3680","volume":"49","author":"J Ding","year":"2016","unstructured":"Ding J, Guo C, Hu P, Chen J, Liu Q, Wu X, Cao Y, Wu J (2016) CSF1 is involved in breast cancer progression through inducing monocyte differentiation and homing. Int J Oncol 49(5):2064\u20132074","journal-title":"Int J Oncol"},{"key":"2503_CR21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12885-015-1076-5","volume":"15","author":"L Yang","year":"2015","unstructured":"Yang L, Wu Q, Xu L, Zhang W, Zhu Y, Liu H, Xu J, Gu J (2015) Increased expression of colony stimulating factor-1 is a predictor of poor prognosis in patients with clear-cell renal cell carcinoma. BMC Cancer 15:67","journal-title":"BMC Cancer"},{"issue":"5","key":"2503_CR22","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1111\/j.1440-1827.2009.02369.x","volume":"59","author":"K Kawamura","year":"2009","unstructured":"Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M (2009) Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. Pathol Int 59(5):300\u2013305","journal-title":"Pathol Int"},{"issue":"5877","key":"2503_CR23","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1126\/science.1154370","volume":"320","author":"H Lin","year":"2008","unstructured":"Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, Halenbeck R, Wu G, Zhou A, Behrens D, Hollenbaugh D, Linnemann T, Qin M, Wong J, Chu K, Doberstein SK, Williams LT (2008) Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science (New York, NY) 320(5877):807\u2013811","journal-title":"Science (New York, NY)"},{"issue":"5","key":"2503_CR24","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00774-013-0476-3","volume":"31","author":"Y Nakamichi","year":"2013","unstructured":"Nakamichi Y, Udagawa N, Takahashi N (2013) IL-34 and CSF-1: similarities and differences. J Bone Miner Metab 31(5):486\u2013495","journal-title":"J Bone Miner Metab"},{"issue":"2","key":"2503_CR25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.cyto.2015.05.029","volume":"76","author":"AI Segaliny","year":"2015","unstructured":"Segaliny AI, Brion R, Brulin B, Maillasson M, Charrier C, Teletchea S, Heymann D (2015) IL-34 and M-CSF form a novel heteromeric cytokine and regulate the M-CSF receptor activation and localization. Cytokine 76(2):170\u2013181","journal-title":"Cytokine"},{"issue":"1","key":"2503_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ijc.29376","volume":"137","author":"AI Segaliny","year":"2015","unstructured":"Segaliny AI, Mohamadi A, Dizier B, Lokajczyk A, Brion R, Lanel R, Amiaud J, Charrier C, Boisson-Vidal C, Heymann D (2015) Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int J Cancer 137(1):73\u201385","journal-title":"Int J Cancer"},{"issue":"20","key":"2503_CR27","doi-asserted-by":"publisher","first-page":"6030","DOI":"10.1158\/0008-5472.CAN-16-1170","volume":"76","author":"M Baghdadi","year":"2016","unstructured":"Baghdadi M, Wada H, Nakanishi S, Abe H, Han N, Putra WE, Endo D, Watari H, Sakuragi N, Hida Y, Kaga K, Miyagi Y, Yokose T, Takano A, Daigo Y, Seino KI (2016) Chemotherapy-induced IL34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells. Cancer Res 76(20):6030\u20136042","journal-title":"Cancer Res"},{"issue":"3","key":"2503_CR28","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/path.4528","volume":"236","author":"Z Baranski","year":"2015","unstructured":"Baranski Z, Booij TH, Cleton-Jansen AM, Price LS, van de Water B, Bovee JV, Hogendoorn PC, Danen EH (2015) Aven-mediated checkpoint kinase control regulates proliferation and resistance to chemotherapy in conventional osteosarcoma. J Pathol 236(3):348\u2013359","journal-title":"J Pathol"},{"issue":"1 Pt 1","key":"2503_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1158\/1078-0432.CCR-0699-3","volume":"10","author":"HM Kluger","year":"2004","unstructured":"Kluger HM, Dolled-Filhart M, Rodov S, Kacinski BM, Camp RL, Rimm DL (2004) Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res 10(1 Pt 1):173\u2013177","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2503_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","volume":"5","author":"MA Cannarile","year":"2017","unstructured":"Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Ruttinger D (2017) Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer 5(1):53","journal-title":"J Immunother Cancer"},{"issue":"7","key":"2503_CR31","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1158\/2326-6066.CIR-16-0309","volume":"5","author":"F Dammeijer","year":"2017","unstructured":"Dammeijer F, Lievense LA, Kaijen-Lambers ME, van Nimwegen M, Bezemer K, Hegmans JP, van Hall T, Hendriks RW, Aerts JG (2017) Depletion of tumor-associated macrophages with a CSF-1R kinase inhibitor enhances antitumor immunity and survival induced by DC immunotherapy. Cancer Immunol Res 5(7):535\u2013546","journal-title":"Cancer Immunol Res"},{"issue":"4","key":"2503_CR32","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1111\/imm.12660","volume":"149","author":"RP Zhou","year":"2016","unstructured":"Zhou RP, Wu XS, Xie YY, Dai BB, Hu W, Ge JF, Chen FH (2016) Functions of interleukin-34 and its emerging association with rheumatoid arthritis. Immunology 149(4):362\u2013373","journal-title":"Immunology"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-018-2503-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00428-018-2503-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-018-2503-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,21]],"date-time":"2019-12-21T19:04:53Z","timestamp":1576955093000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00428-018-2503-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,22]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["2503"],"URL":"https:\/\/doi.org\/10.1007\/s00428-018-2503-1","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,22]]},"assertion":[{"value":"13 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"To ensure patients\u2019 privacy, all samples were managed in a coded fashion and all procedures were conducted according to the Code for Proper Secondary Use of Human Tissue in the Netherlands (Dutch Federation of Medical Scientific Societies).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}